Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder

International Journal of Women's Health

Volumn 1, Issue 1, 2009, Pages 85-95

  Breech, Lesley L ^a   Braverman, Paula K ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Drospirenone; Oral contraceptive pill; Premenstrual dysphoric disorder; Premenstrual syndrome

Indexed keywords

4 AMINOBUTYRIC ACID; ANGIOTENSINOGEN; DESOGESTREL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ENDORPHIN; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETYNODIOL DIACETATE; FOLLITROPIN; GESTAGEN; GESTODENE; GONADORELIN AGONIST; LEVONORGESTREL; NEUROTRANSMITTER; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; PLACEBO; POTASSIUM; PREGNANE DERIVATIVE; PROGESTERONE; SEROTONIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TESTOSTERONE;

4 AMINOBUTYRIC ACID BRAIN LEVEL; ACNE; ANXIETY; BACKACHE; BLOATING; BLOOD PRESSURE; BREAST TENDERNESS; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUID RETENTION; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HIRSUTISM; HUMAN; HYPERKALEMIA; INSOMNIA; INSULIN RESISTANCE; IRRITABILITY; LIFESTYLE MODIFICATION; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; PLACEBO EFFECT; POTASSIUM BLOOD LEVEL; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL LIFE; STRESS MANAGEMENT; SWEATING; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 77953391596     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. American College of Obstetrics and Gynecology. ACOG Practice Bulletin Number 15: Premenstrual Syndrome. Washington, D.C.: American College of Obstetrics and Gynecology; 2000.
2. Mishell DR Jr. Premenstrual disorders: epidemiology and disease burden. Am J Manag Care. 2005;11(16 Suppl):S473-S479.
3. Mortola JF, Girton L, Yen SS. Depressive episodes in premenstrual syndrome. Am J Obstet Gynecol. 1989;161(6 Pt 1):1682-1687.
4. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. Obstet Gynecol. 1990;76(2):302-307.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-Text Revision. 4th ed. Washington, DC.: American Psychiatric Association; 2000.
6. Johnson SR. Premenstrual syndrome, premenstrual dysphoric disorder, and beyond: a clinical primer for practitioners. Obstet Gynecol. 2004; 104(4):845-859.
7. Speroff L, Fritz MA. Clinical Gynecologic Endocrinology and Infertility. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
8. Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;(28 Suppl 3):1-23.
9. Mortola JF. Premenstrual syndrome - pathophysiologic considerations. N Engl J Med. 1998;338(4):256-257.
10. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry. 2000; 61(Suppl 12):17-21.
11. Halbreich U. The diagnosis of premenstrual syndromes and premenstrual dysphoric disorder-clinical procedures and research perspectives. Gynecol Endocrinol. 2004;19(6):320-334.
12. Freeman EW. Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder. CNS Drugs. 2004;18(7):453-468.
13. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med. 2008;53(9 Suppl):729-741.
14. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998;338(4):209-216.
15. Borenstein J, Chiou CF, Dean B, Wong J, Wade S. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med. 2005;47(1):26-33.
16. Borenstein JE, Dean BB, Leifke E, Korner P, Yonkers KA. Differences in symptom scores and health outcomes in premenstrual syndrome. J Womens Health (Larchmt). 2007;16(8):1139-1144.
17. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med. 2003;48(7):515-524.
18. Hylan TR, Sundell K, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France. J Womens Health Gend Based Med. 1999;8(8):1043-1052.
19. Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S. Burden of premenstrual dysphoric disorder on health-related quality of life. J Womens Health (Larchmt). 2008;17(1):113-121.
20. Robinson RL, Swindle RW. Premenstrual symptom severity: impact on social functioning and treatment-seeking behaviors. J Womens Health Gend Based Med. 2000 Sep;9(7):757-768.
21. Lustyk MK, Gerrish WG, Shaver S, Keys SL. Cognitive-behavioral therapy for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch Womens Ment Health. 2009;12(2):85-96.
22. Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediatr Adolesc Gynecol. 2007;20(1):3-12.
23. Rapkin AJ. New treatment approaches for premenstrual disorders. Am J Manag Care. 2005;11(16 Suppl):S480-S491.
24. Emans S, Laufer MR, Goldstein DP, eds. Pediatric and Adolescent Gynecology. 5th ed. Phildelphia, PA: Lippincott, Wiliams & Wilkins; 2005.
25. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull. 1997;33(2):303-309.
26. Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356(9236):1131-1136.
27. Freeman EW, Rickels K, Sondheimer SJ, Polansky M, Xiao S. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry. 2004;161(2):343-351.
28. Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005;66(6):769-773.
29. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med. 1995;332(23):1529-1534.
30. Freeman EW, Rickels K, Yonkers KA, Kunz NR, McPherson M, Upton GV. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98(5 Pt 1):737-744.
31. Cohen LS, Soares CN, Lyster A, Cassano P, Brandes M, Leblanc GA. Efficacy and tolerability of premenstrual use of venlafaxine (flexible dose) in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol. 2004;24(5):540-543.
32. Grady-Weliky TA. Clinical practice. Premenstrual dysphoric disorder. N Engl J Med. 2003;348(5):433-438.
33. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA. 1995;274(1):51-57.
34. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. Obstet Gynecol. 1987;70(1):37-43.
35. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. Arch Gen Psychiatry. 1990;47(3): 270-275.
36. Landen M, Eriksson O, Sundblad C, Andersch B, Naessen T, Eriksson E. Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo. Psychopharmacology (Berl). 2001;155(3):292-298.
37. Wang M, Hammarback S, Lindhe BA, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. Acta Obstet Gynecol Scand. 1995;74(10):803-808.
38. O'Brien PM, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. Br J Obstet Gynaecol. 1979;86(2):142-147.
39. Wyatt K, Dimmock PW, O'Brien PM. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2005;3:CD001396.
40. Shah NR, Jones JB, Aperi J, Shemtov R, Karne A, Borenstein J. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis. Obstet Gynecol. 2008;111(5):1175- 1182.
41. Joffe H, Cohen LS, Harlow BL. Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration. Am J Obstet Gynecol. 2003;189(6):1523-1530.
42. Appel TB, Kambi AA, Birdsall C, et al. A comparison of a new graduated estrogen formulation with three constant-dosed oral contraceptives. Contraception. 1987;35(6):523-532.
43. van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception. 1999;59(4):237-243.
44. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62(1):29-38.
45. Rubig A. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Climacteric. 2003; 6(Suppl 3):49-54.
46. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68(10-13): 891-905.
47. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care. 2000;5(2):124-134.
48. Sangthawan M, Taneepanichskul S. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms. Contraception. 2005;71(1):1-7.
49. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54(2):71-77.
50. Freeman EW, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10(6):561-569.
51. Pearlstein TB, Bachmann GA, Zacur HA, Yonkers KA. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72(6):414-421.
52. Yonkers KA, Brown C, Pearlstein TB, Foegh M, Sampson-Landers C, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 2005;106(3):492-501.
53. Yonkers KA, Niknian M, Marr J. Premenstrual dysphoric disorder symptom cluster improvement by cycle with an oral contraceptive (drospirenone 3 mg/ethinyl estradiol 20 micrograms 24/4) (Abstract for poster session at ACOG 56th Annual Clinical Meeting). Obstetrics and Gynecology. 2008;111:65S.
54. Lopez LM, Kaptein A, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2008;1:CD006586.
55. Borenstein J, Yu HT, Wade S, Chiou CF, Rapkin A. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med. 2003;48(2):79-85.
56. Endrikat J, Sandri M, Gerlinger C, Rubig A, Schmidt W, Fortier M. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Eur J Contracept Reprod Health Care. 2007;12(3):220-228.
57. Taneepanichskul S, Jaisamrarn U, Phupong V. Efficacy of Yasmin in premenstrual symptoms. Arch Gynecol Obstet. 2007;275(6):433-438.
58. Apter D, Borsos A, Baumgartner W, et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. Eur J Contracept Reprod Health Care. 2003;8(1):37-51.
59. Borges LE, Andrade RP, Aldrighi JM, et al. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception. Contraception. 2006;74(6):446-450.
60. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med. 2002;47(1):14-22.
61. Parsey KS, Pong A. An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61(2):105-111.
62. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5(1):25-34.
63. Thorneycroft H, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74(2):123-130.
64. Maloney JM, Dietze P Jr, Watson D, et al. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial. Obstet Gynecol. 2008;112(4):773-781.
65. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, doubleblind, placebo-controlled trial. Contraception. 2008;77(4):249-256.
66. Pehlivanov B, Mitkov M. Efficacy of an oral contraceptive containing drospirenone in the treatment of women with polycystic ovary syndrome. Eur J Contracept Reprod Health Care. 2007;12(1):30-35.
67. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril. 2006;85(2):436-440.
68. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21:1440-1447.
69. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3):191-198.
70. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80(6):1816-1821.
71. Foidart JM. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Eur J Contracept Reprod Health Care. 2000;5(Suppl 3):25-33.
72. Foidart JM. Added benefits of drospirenone for compliance. Climacteric. 2005;8(Suppl 3):28-34.
73. Bayer HealthCare Pharmaceuticals. YAZ combination brief and detailed patient labeling (package insert). Wayne, NJ: Bayer HealthCare Pharmaceuticals, Inc; 2007. p. 1-8.
74. Schürmann R, Blode H, Benda N, Cronin M, Kufner A. Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function. J Clin Pharmacol. 2006;46(8):867-875.
75. Schütt B, Kunz M, Blode H. Coadministration of estradiol/ drospirenone and indomethacin does not cause hyperkalemia in healthy postmenopausal women: a randomized open-label crossover study. J Clin Pharmacol. 2007;47(6):774-781.
76. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142, 475 women-years of observation. Contraception. 2007;75(5): 344-354.
77. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007;110(3):587-593.
78. Gaspard U, Scheen A, Endrikat J, et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception. 2003;67(6):423-429.
79. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception. 2005;71(6):409-416.